- Home
- ALKT vs ZLAB Comparison
ALKT vs ZLAB Comparison
Compare ALKT & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKT
- ZLAB
- Stock Information
- Founded
- ALKT 2007
- ZLAB 2013
- Country
- ALKT United States
- ZLAB China
- Employees
- ALKT N/A
- ZLAB N/A
- Industry
- ALKT EDP Services
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- ALKT Technology
- ZLAB Health Care
- Exchange
- ALKT Nasdaq
- ZLAB Nasdaq
- Market Cap
- ALKT 3.1B
- ZLAB 3.0B
- IPO Year
- ALKT 2021
- ZLAB 2017
- Fundamental
- Price
- ALKT $38.14
- ZLAB $25.85
- Analyst Decision
- ALKT Buy
- ZLAB Strong Buy
- Analyst Count
- ALKT 9
- ZLAB 4
- Target Price
- ALKT $38.00
- ZLAB $52.50
- AVG Volume (30 Days)
- ALKT 1.0M
- ZLAB 1.3M
- Earning Date
- ALKT 10-30-2024
- ZLAB 11-12-2024
- Dividend Yield
- ALKT N/A
- ZLAB N/A
- EPS Growth
- ALKT N/A
- ZLAB N/A
- EPS
- ALKT N/A
- ZLAB N/A
- Revenue
- ALKT $315,562,000.00
- ZLAB $355,748,000.00
- Revenue This Year
- ALKT $28.58
- ZLAB $48.50
- Revenue Next Year
- ALKT $24.11
- ZLAB $47.37
- P/E Ratio
- ALKT N/A
- ZLAB N/A
- Revenue Growth
- ALKT 26.73
- ZLAB 35.01
- 52 Week Low
- ALKT $21.19
- ZLAB $13.48
- 52 Week High
- ALKT $41.36
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- ALKT 54.87
- ZLAB 43.30
- Support Level
- ALKT $35.57
- ZLAB $24.85
- Resistance Level
- ALKT $38.49
- ZLAB $26.77
- Average True Range (ATR)
- ALKT 1.37
- ZLAB 1.47
- MACD
- ALKT -0.22
- ZLAB -0.76
- Stochastic Oscillator
- ALKT 51.53
- ZLAB 20.17
About ALKT Alkami Technology Inc.
Alkami Technology Inc is a cloud-based digital banking solutions provider. Alkami Platform, allows FIs to onboard and engage new users, accelerate revenues and meaningfully improve operational efficiency with the support of a proprietary, true cloud-based, multi-tenant architecture.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.